Breaking News

Eiger Appoints New Executive Leadership

Welcomes Christopher Kurtz as chief technical officer and Sarah Mathieson as senior vice president, Corporate Affairs.

Author Image

By: Charlie Sternberg

Associate Editor

Eiger BioPharmaceuticals Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, has appointed Christopher Kurtz as chief technical officer and Sarah Mathieson as senior vice president, Corporate Affairs.   “This is a pivotal year for Eiger, and I am pleased to welcome Chris and Sarah to the leadership team as our company continues to build momentum across our late-stag...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters